China’s pharmaceutical sector remains insulated from regulatory crackdowns targeting sensitive tech investments, per JW Therapeutics leadership.
China’s pharmaceutical industry continues to operate without disruption from Beijing’s heightened scrutiny of cross-border tech deals, JW Therapeutics CEO Leo Tian said. The company, backed by Bristol Myers Squibb, focuses on cell and gene therapies, which rely heavily on international partnerships.
Recent regulatory actions, including the forced unwinding of Meta’s $2 billion acquisition of AI startup Manus, have raised concerns among global investors. Analysts had warned of broader risks for advanced tech firms with China ties, but Tian stated no impact on JW’s collaborations or pipeline assets.
Tian added that JW is actively pursuing partnerships outside China, underscoring the sector’s resilience amid geopolitical tensions. The pharmaceutical industry is expected to see record biotech licensing deals this year as global drugmakers seek cost-effective innovations.